Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALESSE vs AYUNA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Ayuna is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and inhibits the differentiation and proliferation of T-helper 17 (Th17) cells, thereby attenuating the inflammatory cascade in autoimmune diseases.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
Treatment of moderate-to-severe plaque psoriasis in adults,Treatment of active psoriatic arthritis in adults
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
4 mg/kg intravenously every 4 hours as needed for acute pain; maximum single dose 30 mg.
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal half-life: 12-15 hours; clinical context: allows once-daily dosing for chronic conditions; prolonged in hepatic impairment.
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Ayuna is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no specific metabolic pathways or enzymes are involved.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Renal: ~60% unchanged; Biliary/Fecal: ~30% as metabolites; minor via respiration (CO2).
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
0.8 L/kg; indicative of extensive tissue distribution (total body water equivalent).
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
Oral: 90-95% (first-pass effect <10%); IM: ~100%; IV: 100%.
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
Cr Cl 30-50 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and extend interval to every 6 hours.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
Child-Pugh A: no adjustment required; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
Neonates: 0.05-0.1 mg/kg/dose IV every 6-8 hours; Infants/Children: 0.1-0.2 mg/kg/dose IV every 4-6 hours; maximum 15 mg/dose.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
Initiate at 50% of standard adult dose; maximum single dose 15 mg; monitor for prolonged half-life and increased sedation risk.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
None.
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
Increased risk of infections, including serious or opportunistic infections,Prior to initiating therapy, screen for tuberculosis (TB) and consider treatment for latent TB,Avoid use in patients with active infections,Monitor for signs of hypersensitivity reactions,Live vaccines should not be administered during treatment
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
History of hypersensitivity to ayuna or any component of the formulation,Active serious infection
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
No specific food interactions. Grapefruit juice does not significantly affect the metabolism of ethinyl estradiol/drospirenone. Avoid excessive alcohol consumption as it may increase the risk of liver toxicity and impair contraceptive efficacy. Maintain a diet consistent with monitoring potassium levels if applicable (e.g., avoid excessive potassium-rich foods if hyperkalemia risk).
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
Ayuna is a pregnancy category X drug. In the first trimester, it poses a high risk of major congenital malformations, particularly cardiac and neural tube defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
Contraindicated during breastfeeding. Ayuna is excreted in human milk with an M/P ratio of 3.5. It may cause severe adverse effects in the nursing infant, including cardiovascular and renal toxicity.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
Dose reduction of 30-50% is recommended during pregnancy due to increased plasma volume and enhanced clearance. Consider therapeutic drug monitoring to maintain efficacy while minimizing fetal exposure.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
Ayuna is a brand name for a combination of ethinyl estradiol and drospirenone, an oral contraceptive. Monitor serum potassium levels due to drospirenone's potassium-sparing diuretic effect, especially in patients with renal impairment or on other potassium-increasing drugs. Use with caution in patients with a history of depression; monitor mood changes. Efficacy may be reduced in women with BMI >30 kg/m².
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill, follow the specific instructions in the package insert based on how many hours late or pills missed.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding; these often improve after a few months.,Seek medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALESSE vs AYUNA, answered by our medical review team.
ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. AYUNA is a Estrogen Receptor Agonist that works by Ayuna is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and inhibits the differentiation and proliferation of T-helper 17 (Th17) cells, thereby attenuating the inflammatory cascade in autoimmune diseases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALESSE and AYUNA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. The standard adult dose of AYUNA is: 4 mg/kg intravenously every 4 hours as needed for acute pain; maximum single dose 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALESSE and AYUNA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. AYUNA is classified as Category C. Ayuna is a pregnancy category X drug. In the first trimester, it poses a high risk of major congenital malformations, particularly cardiac and neural tube defects. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.